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Multiple Sclerosis Journal (MSJ) achieved an Impact Factor of 5.280 and the Journal is now ranked 
22/197 in the Clinical Neurology category and 38/261 in the Neurosciences category. It has always 
been the ambition of Alan Thompson, the Editor-in-Chief, since he started with MSJ to get us over 
the five line; a goal shared by the other Editors. We are all delighted with the new Impact Factor. 
Now we must keep moving up!   
As the readers may be aware, this is the highest Impact Factor the Journal has ever achieved. The 
increase is a direct result of the quality of papers published in the Journal, and we would like to 
thank the readership for your help in both authoring and reviewing papers.  
In February 2018 we, the Editors, met in London for the journal’s biennial strategy meeting. During 
this meeting we had an in-depth discussion about the future development and direction of the 
journal. Over the two days we discussed every aspect of the journal and it was clear that the (MSJ) 
benefits from the active support of a dynamic Editorial Board. We are fortunate to have such an 
enthusiastic and engaged group of experts. Together we have reviewed the Editorial Board and we 
look forward to the contributions from the new members. In addition to the Editorial Board changes 
there have been several changes to the Editorial Team of the journal. Professor Jeroen Guerts is now 
Editor for Europe and has stepped down in his role as Controversies Co-Editor due to his increased 
responsibility. Dr Martin E. Duddy has stepped down as Topical Reviews Editor, Dr Alex Rae Grant 
has agreed to succeed him. Professor Matilde Inglese is now Co-Editor of the Controversies working 
alongside Professor Ruth Ann Marrie. Professor Xavier Montalban has stepped down from his role as 
Clinical Cases Editor, succeeded by Dr.Wallace Brownlee. Finally it was also evident from the London 
Editors meeting that there was an increasing awareness by SAGE of the value of a more integrated 
team effort on all fronts for the journal which we  believe will add positively to the efforts of the 
editorial board.  
In the last couple of months the journal has published many strong papers including the 
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis and 
Professor Bill Carroll’s editorial “2017 McDonald MS diagnostic criteria: Evidence-based revisions”. 
We are keen to pursue high quality papers from all areas of the multiple sclerosis field. Therefore we 
would like to welcome more papers on basic and fundamental science in order to support the 
content already published in MSJ. We also think it is important for MSJ to continue publishing papers 
in a reasonable timeframe. As a result we will be reducing the acceptance rate of the journal to 
lessen the time from online publication to issue publication. By reducing the acceptance rate we 
hope that the time to final decision will decrease dramatically (due to the increased rigor and 
decreased workload of the peer review process). This will also strengthen the quality of the papers 
published which should, in turn, have a positive effect on the impact factor.  
Utilising the advice from the most recent Editorial Board meeting, the journal is now set up to 
receive videos (for abstracts or supplementary data) as part of a paper submission. All 
supplementary data for MSJ is hosted on Figshare which allows supplementary data to be viewed 
and accessed by a wider audience.   
The journal continues to pursue special issue proposals so please do get in touch if you have a 
potential topic or idea. Similarly editorials are welcome and we hope that those we do publish are 
received by the readers with interest. The twitter account for the journal (@MSJ_Research) is 
increasing in influence and activity and we hope that those on twitter enjoy and engage with the 
account.  
We believe that these changes will greatly strengthen the Journal and look forward to seeing the 
outcome of the new editorial structure, higher bar for acceptance and increased publication of basic 
and fundamental science papers.  We would also like to take this opportunity to thank our editorial 
board members for their continued enthusiasm and contribution to MSJ.  
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